Company Search:
Advanced Search
Sponsored Links
Genovis AB Company Snapshot
Genovis AB operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Genovis AB with three other companies in this sector in Sweden: Xbrane Biopharma Ab (2017 sales of 20.77 million Swedish Kronor [US$2.24 million] of which 108% was Long-acting injectables), Saniona AB (20.69 million Swedish Kronor [US$2.24 million] ), and Sprint Bioscience AB (23.97 million Swedish Kronor [US$2.59 million] ).

Sales Analysis. During the year ended December of 2017, sales at Genovis AB were SEK 22.87 million (US$2.47 million). This is an increase of 23.3% versus 2016, when the company's sales were SEK 18.54 million. This was the third consecutive year of growth at Genovis AB.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Genovis AB
  Stock Performance Chart for Genovis AB
  Stock Data: Recent Stock Performance:
  Current Price (2/15/2019): 9.80
(Figures in Swedish Kronor)
1 Week 3.2%   13 Weeks 21.6%  
4 Weeks 63.3%   52 Weeks 178.4%  
Genovis AB Key Data:
  Ticker: GENO Country: Sweden
  Exchanges: STO Major Industry: Commercial Services & Supplies
    Sub Industry: Commercial Physical Research
  2017 Sales 22,867,266
(Year Ending Jan 2018).
Employees: 17
  Currency: Swedish Kronor Market Cap: 618,380,000
  Fiscal Yr Ends: December Shares Outstanding: 63,100,000
  Share Type: B Aktie Closely Held Shares: N/A
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.